Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTissue Regenix Group Regulatory News (TRX)

  • This share is currently suspended. It was suspended at a price of 7.23
  • There is currently no data for TRX

Trading Update

7 Jul 2005 07:01

Torex Retail PLC07 July 2005 7 July 2005 Torex Retail Plc Trading Update Torex Retail Plc ("Torex Retail" or "the Group"), is pleased to announce apositive update on trading for the six months ended 30 June 2005. This reflects a strong organic performance in all areas of the Group, includingnew LUCAS contract wins totalling approximately £10 million. LUCAS • New sales success for LUCAS, the Group's market leading JAVA based electronic point of sale (EPOS) solution, with a number of significant contract wins with major international retailers including Deichmann, Reiss and Esprit and UK based retailers including RD Scott, Co-op Home Stores and Mitsukoshi. In addition, LUCAS has now been installed in over 40 stores and more than 150 lanes in the UK and Ireland, with more planned for the next few months. These installations will now act as excellent reference sites for our large prospect pipeline. PERFORMANCE MANAGEMENT PRODUCTS • Significant new wins for SMARTDECISION, the Group's merchandise planning product, including Ann Taylor in America, Modelo Continente in Portugal (part of the €1.6 billion turnover Sonnae Group) and Littlewoods and Oldrids in the UK. PETROLEUM & CONVENIENCE • A new £3.3 million contract for the Petroleum and Conveniencedivision, to install its market leading PoS solution 'Iridium' and backoffice system 'Prism' into 225 stores across the UK. BUSINESS DEVELOPMENT Alphameric Retail, which was acquired in November 2004, is now fully integratedinto Torex Retail, ahead of schedule. Through RSS, which was acquired in May 2005, we are achieving real momentum andare already making strong progress in gaining greater penetration of the USmarket, the largest market in the world for retail systems. In addition, we are currently working towards finalising the recommended offersfor XN Checkout Holdings plc and Anker plc. Both of these businesses meet withour strategic goal of ultimately becoming a global market leader and inparticular are expected to be earnings enhancing. This statement regardingearnings enhancement does not constitute a profit forecast nor should it beinterpreted to mean that earnings per share of Torex Retail for the current orfuture years will necessarily match or exceed the historical published earningsper share of Torex Retail. INTERIM RESULTS The Board intends to announce results for the six months ended 30 June 2005 inlate September and expects these results to be consistent with full yearmanagement expectations. The Group continues to enjoy a high level of revenuevisibility, based on strong recurring revenues from its blue-chip customer base.This, coupled with its new business pipeline, gives the directors confidenceabout the Group's prospects for 2005 and beyond. Chris Moore, Chief Executive, Torex Retail Plc, comments: "I am delighted with the progress we have made in all areas of our operationsduring the first half of this year. The cyclical upturn in the market is nowgathering momentum, most notably evidenced by our significant new contract winsfor LUCAS. Coupled with this, our accelerated growth plan through acquisitionsis already positioning us such that we are currently in discussions with some ofthe world's largest retailers as potential customers, both in Europe and theUSA. Enquiries: Torex Retail Plc 0870 050 9900 Chris Moore, Chief Executive Richard Thompson, Group Finance Director Citigate Dewe Rogerson 020 7638 9571 Ginny Pulbrook / Seb Hoyle This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
22nd Nov 20227:00 amRNSDistribution agreement - OrthoPure® XT in Germany
14th Nov 20226:05 pmRNSHolding(s) in Company
7th Nov 20222:35 pmRNSHolding(s) in Company
29th Sep 202210:13 amRNSDirector/PDMR Shareholding
27th Sep 20227:15 amEQSHardman & Co Research on Tissue Regenix (TRX): Operating leverage
7th Sep 20227:00 amRNSHalf-year Report
22nd Aug 20223:31 pmRNSHolding(s) in Company
18th Aug 20225:36 pmRNSHolding(s) in Company
18th Aug 20222:10 pmRNSHolding(s) in Company
11th Aug 20224:30 pmEQSHardman & Co Research: Q&A on Tissue Regenix Group plc: Significantly undervalued which should correct
11th Aug 202212:46 pmRNSHolding(s) in Company
11th Aug 202212:17 pmRNSHolding(s) in Company
11th Aug 20227:00 amRNSConfirmation of Interim Results
5th Aug 20223:19 pmRNSHolding(s) in Company
1st Aug 20223:14 pmRNSHolding(s) in Company
19th Jul 20222:30 pmEQSHardman & Co Research : Tissue Regenix (TRX): Strong 1H’22 sales suggest upside potential
19th Jul 20227:00 amRNSHalf Year Trading Update and Notice of Results
18th Jul 20222:42 pmRNSHolding(s) in Company
18th Jul 20221:33 pmRNSHolding(s) in Company
15th Jul 20225:29 pmRNSHolding(s) in Company
27th Jun 20226:04 pmRNSHolding(s) in Company
27th Jun 202212:58 pmRNSHolding(s) in Company
16th Jun 20221:27 pmRNSExercise of Options and Total Voting Rights
28th Apr 20227:00 amRNSOrthoPure®XT clinical results presentation
26th Apr 20224:19 pmRNSResult of AGM
20th Apr 20224:26 pmRNSDirector/PDMR Shareholding
19th Apr 20227:15 amEQSHardman & Co Research: Tissue Regenix (TRX) On pathway to sustainability
8th Apr 20227:00 amRNSGrant of share options
6th Apr 20222:59 pmRNSDirector/PDMR Shareholding
15th Mar 20227:00 amRNSFinal year results for the year ended 31 Dec 2021
9th Mar 20227:00 amRNSDistribution agreement for OrthoPure® XT
2nd Mar 20227:00 amRNSNotice of Results
10th Feb 20223:45 pmRNSAdditional Director Disclosures
27th Jan 20227:00 amRNSFull Year Trading update
23rd Dec 20217:00 amRNSDirector/PDMR Shareholding
21st Dec 20212:06 pmRNSSecond Price Monitoring Extn
21st Dec 20212:01 pmRNSPrice Monitoring Extension
19th Oct 20211:15 pmEQSHardman & Co Research: Tissue Regenix (TRX): Faster-than-anticipated recovery
8th Oct 20217:00 amRNSHolding(s) in Company
5th Oct 20214:44 pmRNSHolding(s) in Company
28th Sep 20217:00 amRNSHolding(s) in Company
24th Sep 20212:05 pmRNSDirector/PDMR Shareholding
9th Sep 20214:35 pmRNSDirector/PDMR Shareholding
8th Sep 20217:00 amRNSHalf-year Report
1st Sep 20217:00 amRNSLaunch of DermaPure® Meshed and VNEWTM
1st Sep 20217:00 amRNSNotice of Results
16th Aug 20217:00 amRNSHolding(s) in Company
14th Jul 20213:15 pmEQSHardman & Co Research: Q&A with Dr Martin Hall on Tissue Regenix Group Plc: New capacity now on stream
30th Jun 202111:56 amEQSHardman & Co Research: Tissue Regenix (TRX): Poised for growth
29th Jun 20211:00 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.